Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS ‐ AP ‐combo and SURPASS ‐3

Sep 16, 2025Diabetes, obesity & metabolism

Effectiveness and safety of tirzepatide in Korean adults with type 2 diabetes: Analysis from SURPASS-AP-combo and SURPASS-3 trials

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In Korean patients with type 2 diabetes treated with tirzepatide, HbA1c levels were reduced by 2.75% to 3.25% from baseline.

HbA1c targets of <7.0% and ≤6.5% were achieved by 84.6% to 100% of participants at week 40.
Body weight reductions ranged from -6.8% to -10.9% from baseline.
69.2% to 85.2% of tirzepatide recipients achieved the composite endpoint of HbA1c ≤6.5% without body weight gain or significant hypoglycaemia.
Results in the Korean subgroup were consistent with those observed in the larger SURPASS-AP-Combo and SURPASS-3 trials.
The safety profile of tirzepatide in Korean participants was similar to that of the overall trial populations.

AI simplified

AIMS: This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D).

MATERIALS AND METHODS: Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multicentre, randomised, open-label, parallel-group, phase 3 trials SURPASS-AP-Combo and SURPASS-3 were extracted and analysed. Efficacy (change from baseline in glycated haemoglobin [HbA1c] and body weight, and proportions of participants achieving HbA1c and body weight targets) and safety endpoints were evaluated at week 40 (SURPASS-AP Combo) and week 52 (SURPASS-3).

RESULTS: In the SURPASS-AP-Combo and SURPASS-3, 79 of 687 and 27 of 1079 tirzepatide recipients, respectively, were Korean. In Korean participants in SURPASS-AP-Combo across all tirzepatide doses, least squares mean (LSM) HbA1c was reduced from baseline by 2.75% to 3.25% and HbA1c targets of <7.0% and ≤6.5% were achieved by 84.6% to 100% at week 40; LSM body weight reductions of -6.8% to -10.9% from baseline were achieved. The composite endpoint of HbA1c ≤6.5% without body weight gain or clinically significant documented symptomatic or severe hypoglycaemia was achieved by 69.2% to 85.2% of tirzepatide recipients. Findings were similar in Korean participants of SURPASS-3. The safety profile of tirzepatide in Korean participants was generally consistent with that in the overall SURPASS-AP-Combo and SURPASS-3 populations.

CONCLUSIONS: Consistent with the overall results of the SURPASS-AP-Combo and SURPASS-3 trials, this post hoc subgroup analysis found clinically meaningful reductions in HbA1c and body weight after treatment periods of 40 to 52 weeks in Koreans with T2D treated with tirzepatide.

Full Text

Full text is available at the source.

View full text ↗

Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS ‐ AP ‐combo and SURPASS ‐3

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief